Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial
Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial
复制标题
DOI：
10.1016/j.clnu.2016.08.015
复制
发表时间：
2017-10-01
影响因子：
6.3
通讯作者：
Asemi, Zatollah
中科院分区：
文献类型：
--
作者：
Kouchaki, Ebrahim;Tamtaji, Omid Reza;Asemi, Zatollah
背景和目标：本试验旨在评估益生菌摄入对多发性硬化症（MS）患者残疾、心理健康和代谢状况的影响。方法：本随机双盲安慰剂对照临床试验在60例MS患者中进行。参与者被随机分配到两组，接受益生菌胶囊（n = 30）或含淀粉的安慰剂（n = 30），持续12周。分别于干预前和干预后12周进行扩展残疾状态量表（EDSS）评分和心理健康指标的测定。与安慰剂相比，益生菌摄入改善了EDSS（-0.3 +/- 0.6 vs. +0.1 +/- 03，P = 0.001），贝克抑郁量表（-5.6 +/- 4.9 vs. -1.1 +/- 3.4，P < 0.001），一般健康问卷（-9.1 +/- 6.2 vs. -2.6 +/- 6.4，P < 0.001）和抑郁焦虑和压力量表（-16.5 +/- 12.9 vs. -6.2 +/- 11.0，P = 0.001）。此外，高敏C反应蛋白的变化（-1.3 +/- 3.5 vs. +0.4 +/- 1.4 μ g/mL，P = 0.01），血浆一氧化氮代谢物（+1.0 +/- 7.9 vs. -6.0 +/- 8.3 μ mol/L，P = 0.002）和丙二醛（MDA）（+0.009 +/- 0.4 vs. +0.3 +/- 0.5 μ mol/L，P = 0.04）与安慰剂组中这些参数的变化显著不同。此外，益生菌胶囊的消耗显著降低血清胰岛素（-2.9 +/- 3.7 vs. +1.1 +/- 4.8 mu IU/mL，P < 0.001），评估-估计胰岛素抵抗的稳态模型（-0.6 +/- 0.8 vs. +0.2 +/- 1.0，P = 0.001），β细胞功能（-12.1 +/- 15.5 vs. +4.4 +/- 17.5，P < 0.001）和总-/HDL-胆固醇（-0.1 +/- 03 vs. 0.1 +/- 03，P = 0.02），并显著增加定量胰岛素敏感性检查指数（+0.01 +/- 0.02 vs. -0.005 +/- 0.01，P < 0.001）和HDL-胆固醇水平（2.7 +/- 3.4 vs. 0.9 +/- 2.9 mg/dL，P = 0.02）与安慰剂相比。我们的研究表明，在MS受试者中使用益生菌胶囊12周对EDSS、心理健康参数、炎症因子、胰岛素抵抗标志物、HDL-、总-/HDL-胆固醇和MDA水平。(C)2016爱思唯尔有限公司和欧洲临床营养与代谢学会。All rights reserved.
Background & aims: This trial was performed to evaluate the effects of probiotic intake on disability, mental health and metabolic condition in subjects with multiple sclerosis (MS).Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 60 MS patients. Participants were randomly allocated into two groups to receive either a probiotic capsule (n = 30) or placebo containing starch (n = 30) for 12 weeks. Expanded disability status scale (EDSS) scoring and parameters of mental health were recorded at the baseline and 12 weeks after the intervention.Results: Compared with the placebo, probiotic intake improved EDSS (-0.3 +/- 0.6 vs. +0.1 +/- 03, P = 0.001), beck depression inventory (-5.6 +/- 4.9 vs. -1.1 +/- 3.4, P < 0.001), general health questionnaire (-9.1 +/- 6.2 vs. -2.6 +/- 6.4, P < 0.001) and depression anxiety and stress scale (-16.5 +/- 12.9 vs. -6.2 +/- 11.0, P = 0.001). In addition, changes in high-sensitivity C-reactive protein (-1.3 +/- 3.5 vs. +0.4 +/- 1.4 mu g/mL, P = 0.01), plasma nitric oxide metabolites (+1.0 +/- 7.9 vs. -6.0 +/- 8.3 mu mol/L, P = 0.002) and malondialdehyde (MDA) (+0.009 +/- 0.4 vs. +0.3 +/- 0.5 mu mol/L, P = 0.04) in the probiotic group were significantly different from the changes in these parameters in the placebo group. Additionally, the consumption of probiotic capsule significantly decreased serum insulin (-2.9 +/- 3.7 vs. +1.1 +/- 4.8 mu IU/mL, P < 0.001), homeostasis model of assessment-estimated insulin resistance (-0.6 +/- 0.8 vs. +0.2 +/- 1.0, P = 0.001), Beta cell function (-12.1 +/- 15.5 vs. +4.4 +/- 17.5, P < 0.001) and total-/HDL-cholesterol (-0.1 +/- 03 vs. 0.1 +/- 03, P = 0.02), and significantly increased quantitative insulin sensitivity check index (+0.01 +/- 0.02 vs. -0.005 +/- 0.01, P < 0.001) and HDL-cholesterol levels (2.7 +/- 3.4 vs. 0.9 +/- 2.9 mg/dL, P = 0.02) compared with the placebo.Conclusions: Our study demonstrated that the use of probiotic capsule for 12 weeks among subjects with MS had favorable effects on EDSS, parameters of mental health, inflammatory factors, markers of insulin resistance, HDL-, total-/HDL-cholesterol and MDA levels. (C) 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.